80 related articles for article (PubMed ID: 12170384)
1. HSV1716 persistence in primary human glioma cells in vitro.
Harland J; Papanastassiou V; Brown SM
Gene Ther; 2002 Sep; 9(17):1194-8. PubMed ID: 12170384
[TBL] [Abstract][Full Text] [Related]
2. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.
Harrow S; Papanastassiou V; Harland J; Mabbs R; Petty R; Fraser M; Hadley D; Patterson J; Brown SM; Rampling R
Gene Ther; 2004 Nov; 11(22):1648-58. PubMed ID: 15334111
[TBL] [Abstract][Full Text] [Related]
3. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.
Papanastassiou V; Rampling R; Fraser M; Petty R; Hadley D; Nicoll J; Harland J; Mabbs R; Brown M
Gene Ther; 2002 Mar; 9(6):398-406. PubMed ID: 11960316
[TBL] [Abstract][Full Text] [Related]
4. Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours.
Detta A; Harland J; Hanif I; Brown SM; Cruickshank G
J Gene Med; 2003 Aug; 5(8):681-9. PubMed ID: 12898637
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
6. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.
MacKie RM; Stewart B; Brown SM
Lancet; 2001 Feb; 357(9255):525-6. PubMed ID: 11229673
[TBL] [Abstract][Full Text] [Related]
7. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
Friedman A; Tian JP; Fulci G; Chiocca EA; Wang J
Cancer Res; 2006 Feb; 66(4):2314-9. PubMed ID: 16489036
[TBL] [Abstract][Full Text] [Related]
8. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
[TBL] [Abstract][Full Text] [Related]
9. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
10. [Gene therapy for brain tumors using herpes simplex virus vector].
Toda M
Nihon Rinsho; 2005 Sep; 63 Suppl 9():510-4. PubMed ID: 16201573
[No Abstract] [Full Text] [Related]
11. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Quigg M; Mairs RJ; Brown SM; Harland J; Dunn P; Rampling R; Livingstone A; Wilson L; Boyd M
Med Chem; 2005 Sep; 1(5):423-9. PubMed ID: 16787326
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus type 1 strain HSV1716 grown in baby hamster kidney cells has altered tropism for nonpermissive Chinese hamster ovary cells compared to HSV1716 grown in vero cells.
Conner J; Rixon FJ; Brown SM
J Virol; 2005 Aug; 79(15):9970-81. PubMed ID: 16014957
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
14. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
Hellums EK; Markert JM; Parker JN; He B; Perbal B; Roizman B; Whitley RJ; Langford CP; Bharara S; Gillespie GY
Neuro Oncol; 2005 Jul; 7(3):213-24. PubMed ID: 16053696
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
[TBL] [Abstract][Full Text] [Related]
16. Assessment of 123I-FIAU imaging of herpes simplex viral gene expression in the treatment of glioma.
Dempsey MF; Wyper D; Owens J; Pimlott S; Papanastassiou V; Patterson J; Hadley DM; Nicol A; Rampling R; Brown SM
Nucl Med Commun; 2006 Aug; 27(8):611-7. PubMed ID: 16829761
[TBL] [Abstract][Full Text] [Related]
17. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells.
Li S; Tokuyama T; Yamamoto J; Koide M; Yokota N; Namba H
Cancer Gene Ther; 2005 Jul; 12(7):600-7. PubMed ID: 15775995
[TBL] [Abstract][Full Text] [Related]
18. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
19. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
Conner J; Braidwood L; Brown SM
Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
Geoerger B; Vassal G; Opolon P; Dirven CM; Morizet J; Laudani L; Grill J; Giaccone G; Vandertop WP; Gerritsen WR; van Beusechem VW
Cancer Res; 2004 Aug; 64(16):5753-9. PubMed ID: 15313916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
